Shen Zhong-Ying, Shen Jian, Chen Ming-Hua, Wu Xian-Ying, Wu Min-Hua, Zeng Yi
Department of Pathology, College of Medicine, Shantou University, Shantou 515031, PR China.
Oncol Rep. 2003 Nov-Dec;10(6):1869-74.
To investigate the antitumor action of arsenic trioxide (As2O3) by intratumoral injection into solid tumors, tumor growth inhibition (TGI) and angiogenesis of heterotransplanted esophageal carcinoma in mice was carried out. The cultured human esophageal carcinoma cells were inoculated into both laterals of the abdominal wall of severe combined immunodeficient (SCID) mice. When both lateral tumors had grown to about 10x8x5 mm(3), the right tumors were treated with an intratumoral injection of As2O3 in dosage of 1, 5 and 10 microg per day, respectively, for 10 days sequentially. Left tumors were treated with PBS (phosphate buffer solution) as control. The weight of transplanted tumor masses were measured and counted for TGI. The tissue of tumor, liver, kidney, heart, lung and brain was examined histopathologically and tumor tissues were examined by light- or electron-microscope. Ki-67 and CD34 were assessed by immunohistochemistry and positive nuclei of Ki-67 and microvessel density (MVD) labeled by CD34 were measured. The results revealed that on the 20th day after the first injection, As2O3-treated tumors were suppressed markedly as compared with the contrarily situated tumor, accompanied by a marked apoptosis and necrosis in tumor cells. The tissue of liver, kidney, heart, lung and brain was unaffected by As2O3. MVD in tumor tissue was decreased in the right side tumor with the significant difference in the 5 micro g and 10 micro g group (p<0.01). TGI was 5.80 (p>0.05), 58.66 (p<0.01) and 73.97% (p<0.01) in the 1, 5 and 10 micro g groups respectively, but 2.21% (p>0.05) in the control group. Conclusively, a repeated administration of As2O3 (5 and 10 microg x 10) induced an increase of tumor growth inhibition and decrease of angiogenesis in the solid tumor in tumor progressive periods. These results suggest that intra-tumoral injection of As2O3 may be investigated as a modality to treat some solid tumors.
为研究经瘤内注射三氧化二砷(As2O3)对实体瘤的抗肿瘤作用,进行了小鼠异种移植食管癌的肿瘤生长抑制(TGI)和血管生成研究。将培养的人食管癌细胞接种到严重联合免疫缺陷(SCID)小鼠腹壁两侧。当两侧肿瘤长至约10×8×5mm³时,右侧肿瘤分别以每天1、5和10μg的剂量进行瘤内注射As2O3,连续注射10天。左侧肿瘤用磷酸盐缓冲液(PBS)作为对照进行处理。测量移植瘤块的重量并计算TGI。对肿瘤、肝脏、肾脏、心脏、肺和脑组织进行组织病理学检查,肿瘤组织进行光镜或电镜检查。通过免疫组织化学评估Ki-67和CD34,并测量Ki-67阳性细胞核和CD34标记的微血管密度(MVD)。结果显示,首次注射后第20天,与对侧肿瘤相比,As2O3处理的肿瘤明显受到抑制,伴有肿瘤细胞明显的凋亡和坏死。肝脏、肾脏、心脏、肺和脑组织未受As2O3影响。右侧肿瘤组织中的MVD降低,5μg和10μg组有显著差异(p<0.01)。1、5和10μg组的TGI分别为5.80(p>0.05)、58.66(p<0.01)和73.97%(p<0.01),而对照组为2.21%(p>0.05)。总之,重复给予As2O3(5和10μg×10)可导致肿瘤进展期实体瘤的肿瘤生长抑制增加和血管生成减少。这些结果表明,瘤内注射As2O3可作为治疗某些实体瘤的一种方式进行研究。